期刊文献+

代谢综合征患者脂蛋白相关磷脂酶A2活性变化的特征

The Characteristics of Lipoprotein-associated Phospholipase A2 Activity in the Metabolic Syndrome
下载PDF
导出
摘要 目的:脂蛋白相关磷脂酶A2是一项新的与低水平炎症反应有关的炎性标志物,该研究通过检测代谢综合征患者中该酶水平的变化,探讨代谢综合征的炎症反应机制。方法:采用病例-对照研究,健康对照组与代谢综合征组各65例,均为男性。测定两组人群血浆中脂蛋白相关磷脂酶A2活性。结果:与健康对照组相比,代谢综合征患者血浆中脂蛋白相关磷脂酶A2活性较高(76.98比60.58μmol/L.min,P<0.001)。结论:脂蛋白相关磷脂酶A2活性在代谢综合征患者中升高,表现出低水平的炎症反应。 Objective:Lipoprotein-associated phospholipase A2(Lp-PLA2) is a novel inflammation marker associated with the low-grade inflammatory action.The objective of this study is to investigate its changes in the metabolic syndrome(MS).Methods:A case-control study was used including 65 cases and 65 controls and all were male.The activity of plasma Lp-PLA2 was measured.Results:Compared to the control group,the total plasma Lp-PLA2 activity(76.98 vs.60.58 μmol/L·min,P〈0.001) was higher in the MS group than in the control group.Conclusion:The activity of Lp-PLA2 is higher in the MS patients,indicating that the low-grade inflammation may exist in the MS patients.
出处 《华西医学》 CAS 2008年第2期338-339,共2页 West China Medical Journal
关键词 脂蛋白相关磷脂酶A2 血小板活化因子乙酰水解酶 代谢综合征 炎症 lipoprotein-associated phospholipase A2 platelet-activating factor-acetylhydrolase metabolic syndrome inflammation
  • 相关文献

参考文献9

  • 1Zalewski A,Macphee C.Role of lipoprotein-associated phospholipase A2 in atherosclerosis:biology,epidemiology,and possible therapeutic target[J].Atheroscler Thromb Vasc Biol,2005,25(5):923-931.
  • 2Noto H,Hara M,Karasawa K,et al.Human plasma platelet-activating factor acetylhydrolase binds to all the murine lipoprotein,conferring protection against oxidative stress[J].Atheroscler Thromb Vasc Biol,2003,23(5):829-835.
  • 3Quarck R,De Geest B,Stengel D,et al.Adenovirus-mediated gene transfer of human platelet-activating factor acetylhydrolase injury-induced neointima formation and reduces spontaneous atherosclerosis in apolipoprotein E-deficient mice[J].Circulation,2001,103(20):2495-2500.
  • 4Sudhir K.Clinical review:Lipoprotein-associated phospholipase A2,a novel inflammatory biomarker and independent risk predictor for cardiovascular disease[J].J Clin Endocrinol Metab,2005,90(5):3100-3105.
  • 5Grundy SM,Brewer Jr.HB,Cleeman JI,et al.Definition of metabolic syndrome:Report of the National Heart,Lung,and Blood Institute/American Heart Association conference on scientific issues related to definition[J].Circulation,2004,109(3):433-438.
  • 6Grundy SM,Cleeman JI,Merz CN,et al.Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines[J].Circulation,2004,110(2):227-239.
  • 7中华医学会糖尿病学分会代谢综合征研究协作组.中华医学会糖尿病学分会关于代谢综合征的建议[J].中国糖尿病杂志,2004,12(3):156-161. 被引量:3044
  • 8Ford ES.The metabolic syndrome and C-reactive protein,fibrinogen,and leukocyte count:Finding from the Third· National Health and Nutrition Examination Survey[J].Atherosclerosis,2003,168:351-358.
  • 9Festa AD,Agostino JrR,Howard G,et al.Chronic subclinical inflammation as part of the insulin resistance syndrome:The Insulin Resistance Atherosclerosis Study(IRAS)[J].Circulation,2004,102(1):42-47.

二级参考文献3

共引文献3043

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部